221 related articles for article (PubMed ID: 8469286)
1. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma.
Tao MH; Levy R
Nature; 1993 Apr; 362(6422):755-8. PubMed ID: 8469286
[TBL] [Abstract][Full Text] [Related]
2. Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor.
Chen TT; Tao MH; Levy R
J Immunol; 1994 Nov; 153(10):4775-87. PubMed ID: 7525715
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
[TBL] [Abstract][Full Text] [Related]
4. Rapid expression of vaccine proteins for B-cell lymphoma in a cell-free system.
Yang J; Kanter G; Voloshin A; Michel-Reydellet N; Velkeen H; Levy R; Swartz JR
Biotechnol Bioeng; 2005 Mar; 89(5):503-11. PubMed ID: 15669088
[TBL] [Abstract][Full Text] [Related]
5. A nine-amino acid peptide from IL-1beta augments antitumor immune responses induced by protein and DNA vaccines.
Hakim I; Levy S; Levy R
J Immunol; 1996 Dec; 157(12):5503-11. PubMed ID: 8955200
[TBL] [Abstract][Full Text] [Related]
6. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
7. A genetic approach to idiotypic vaccination for B cell lymphoma.
Stevenson FK; Zhu D; King CA; Ashworth LJ; Kumar S; Thompsett A; Hawkins RE
Ann N Y Acad Sci; 1995 Nov; 772():212-26. PubMed ID: 8546396
[TBL] [Abstract][Full Text] [Related]
8. Induction of tumor immunity by autologous B lymphoma cells expressing a genetically engineered idiotype.
Selmayr M; Strehl J; Kremer JP; Kremmer E; Doenecke A; Hallek M; Menzel H; Thielemans K; Thierfelder S; Mocikat R
Gene Ther; 1999 May; 6(5):778-84. PubMed ID: 10505101
[TBL] [Abstract][Full Text] [Related]
9. DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection.
Syrengelas AD; Levy R
J Immunol; 1999 Apr; 162(8):4790-5. PubMed ID: 10202021
[TBL] [Abstract][Full Text] [Related]
10. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity.
Levitsky HI; Montgomery J; Ahmadzadeh M; Staveley-O'Carroll K; Guarnieri F; Longo DL; Kwak LW
J Immunol; 1996 May; 156(10):3858-65. PubMed ID: 8621924
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal anti-idiotype antibody 6G6.C4 fused to GM-CSF is capable of breaking tolerance to carcinoembryonic antigen (CEA) in CEA-transgenic mice.
Schwegler C; Dorn-Beineke A; Nittka S; Stocking C; Neumaier M
Cancer Res; 2005 Mar; 65(5):1925-33. PubMed ID: 15753392
[TBL] [Abstract][Full Text] [Related]
12. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
13. Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model.
Kwak LW; Campbell M; Levy R
Cancer Detect Prev; 1991; 15(4):323-5. PubMed ID: 1794139
[TBL] [Abstract][Full Text] [Related]
14. Prime-boost vaccines encoding an intracellular idiotype/GM-CSF fusion protein induce protective cell-mediated immunity in murine pre-B cell leukemia.
Pasquini S; Peralta S; Missiaglia E; Carta L; Lemoine NR
Gene Ther; 2002 Apr; 9(8):503-10. PubMed ID: 11948375
[TBL] [Abstract][Full Text] [Related]
15. Granulocyte-macrophage colony-stimulating factor-producing tumour vaccines.
Rössner P; Bubeník J; Sobota V; Indrová M; Hájková R; Mendoza L; Jandlová T; Símová J
Folia Biol (Praha); 1999; 45(5):173-7. PubMed ID: 10730885
[TBL] [Abstract][Full Text] [Related]
16. Cloning of idiotype immunoglobulin genes in B cell lymphomas by anchored PCR and production of individual recombinant idiotype vaccines in Escherichia coli.
Bertinetti C; Simon F; Zirlik K; Heining-Mikesch K; Pfeifer D; Osterroth F; Rosenthal FM; Veelken H
Eur J Haematol; 2006 Nov; 77(5):395-402. PubMed ID: 16879605
[TBL] [Abstract][Full Text] [Related]
17. Induction of autoantibody responses to GM-CSF by hyperimmunization with an Id-GM-CSF fusion protein.
Chen TT; Levy R
J Immunol; 1995 Apr; 154(7):3105-17. PubMed ID: 7897201
[TBL] [Abstract][Full Text] [Related]
18. Cancer. Fusion potential for vaccines.
Taylor-Papadimitriou J; Balkwill F
Nature; 1993 Apr; 362(6422):695. PubMed ID: 8469278
[No Abstract] [Full Text] [Related]
19. Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells.
Rinaldi M; Ria F; Parrella P; Signori E; Serra A; Ciafrè SA; Vespignani I; Lazzari M; Farace MG; Saglio G; Fazio VM
Cancer Res; 2001 Feb; 61(4):1555-62. PubMed ID: 11245465
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.
Bertinetti C; Zirlik K; Heining-Mikesch K; Ihorst G; Dierbach H; Waller CF; Veelken H
Cancer Res; 2006 Apr; 66(8):4496-502. PubMed ID: 16618777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
